February 9, 2011 / 12:07 PM / 7 years ago

UPDATE 1-QLT eye drug disappoints in mid-stage trial

Feb 9 (Reuters) - Canadian pharmaceutical company QLT Inc QLT.TO said a mid-stage trial for its experimental allergic conjunctivitis treatment showed the drug did not reduce symptoms compared to a dummy drug. QLT said it does not plan to begin further clinical trials of the treatment — olopatadine punctal plug delivery system or O-PPDS — pending the outcome of another ongoing trial in glaucoma.

The company, however, said the drug was generally safe and well tolerated. (Reporting by Bhaswati Mukhopadhyay and Esha Dey in Bangalore; Editing by Jarshad Kakkrakandy)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below